Search Results - "Burton, James R."

Drug–drug interactions during antiviral therapy for chronic hepatitis C by Kiser, Jennifer J., Burton, James R., Everson, Gregory T.

“…The development of direct-acting antiviral therapies is a major advance in HCV treatment and numerous agents are in various stages of clinical development…”
Get full text

The Loss of a Great One by Burton, James R.

Get full text

The within-individual reproducibility of the disease severity index from the HepQuant SHUNT test of liver function and physiology by Burton, James R., Helmke, Steven, Lauriski, Shannon, Kittelson, John, Everson, Gregory T.

“…The HepQuant SHUNT test quantifies liver function and blood flow using systemic and portal clearances of cholate. The test can identify the risk of…”
Get full text

Interferon‐free therapy for genotype 1 hepatitis C in liver transplant recipients: Real‐world experience from the hepatitis C therapeutic registry and research network by Brown, Robert S., O'Leary, Jacqueline G., Reddy, K. Rajender, Kuo, Alexander, Morelli, Giuseppe J., Burton, James R., Stravitz, R. Todd, Durand, Christine, Bisceglie, Adrian M., Kwo, Paul, Frenette, Catherine T., Stewart, Thomas G., Nelson, David R., Fried, Michael W., Terrault, Norah A.

“…Recurrent infection with the hepatitis C virus (HCV) after liver transplantation (LT) is associated with decreased graft and patient survival. Achieving…”
Get full text

Long-term quality of life after liver donation in the adult to adult living donor liver transplantation cohort study (A2ALL) by Ladner, Daniela P, Dew, Mary Amanda, Forney, Sarah, Gillespie, Brenda W, Brown, Robert S, Merion, Robert M, Freise, Chris E, Hayashi, Paul H, Hong, Johnny C, Ashworth, April, Berg, Carl L, Burton, James R, Shaked, Abraham, Butt, Zeeshan

“…Graphical abstract…”
Get full text

Incidence and Predictors of 30-Day Readmission Among Patients Hospitalized for Advanced Liver Disease by Berman, Kenneth, Tandra, Sweta, Forssell, Kate, Vuppalanchi, Raj, Burton, James R, Nguyen, James, Mullis, Devonne, Kwo, Paul, Chalasani, Naga

“…Background & Aims The rate of readmission to the hospital 30 days after discharge (30-day readmission rate) is used as a quality measure for hospitalized…”
Get full text

An Interferon-free Antiviral Regimen for HCV after Liver Transplantation by Kwo, Paul Y, Mantry, Parvez S, Coakley, Eoin, Te, Helen S, Vargas, Hugo E, Brown, Robert, Gordon, Fredric, Levitsky, Josh, Terrault, Norah A, Burton, James R, Xie, Wangang, Setze, Carolyn, Badri, Prajakta, Pilot-Matias, Tami, Vilchez, Regis A, Forns, Xavier

“…In this study, 34 liver-transplant recipients with recurrent HCV genotype 1 infection were treated with the interferon-free regimen of ombitasvir–ABT-450/r,…”
Get full text

Reply to “Living liver donation in previous kidney donors: A single‐center experience” by Jackson, Whitney E., Kriss, Michael S., Burton, James R., Nydam, Trevor L., Conzen, Kendra D., Pomposelli, James J., Pomfret, Elizabeth A.

Get full text

Differential effects of plasma and red blood cell transfusions on acute lung injury and infection risk following liver transplantation by Benson, Alexander B., Burton, James R., Austin, Gregory L., Biggins, Scott W., Zimmerman, Michael A., Kam, Igal, Mandell, Susan, Silliman, Christopher C., Rosen, Hugo, Moss, Marc

“…Patients with chronic liver disease have an increased risk of developing transfusion‐related acute lung injury (TRALI) from plasma‐containing blood products…”
Get full text

Prevalence and Predictors of Patient-Reported Long-term Mental and Physical Health After Donation in the Adult-to-Adult Living-Donor Liver Transplantation Cohort Study by Dew, Mary Amanda, Butt, Zeeshan, Liu, Qian, Simpson, Mary Ann, Zee, Jarcy, Ladner, Daniela P., Holtzman, Susan, Smith, Abigail R., Pomfret, Elizabeth A., Merion, Robert M., Gillespie, Brenda W., Sherker, Averell H., Fisher, Robert A., Olthoff, Kim M., Burton, James R., Terrault, Norah A., Fox, Alyson N., DiMartini, Andrea F.

“…BACKGROUNDProspective and longitudinal studies have examined liver donors’ medical outcomes beyond the first 1 to 2 years postdonation. There is no analogous…”
Get full text

Compartmental model describing the physiological basis for the HepQuant SHUNT test by McRae, Michael P., Helmke, Steve M., Burton, James R., Everson, Gregory T.

“…The HepQuant SHUNT test quantifies hepatic functional impairment from the simultaneous clearance of cholate from the systemic and portal circulations for the…”
Get full text

Challenging the Traditional Paradigm of Supply and Demand in Pediatric Liver Transplantation Through Nondirected Living Donation: A Case Series by Yoeli, Dor, Jackson, Whitney E., Adams, Megan A., Wachs, Michael E., Sundaram, Shikha S., Sater, Anna, Cisek, Jaime R., Choudhury, Rashikh A., Nydam, Trevor L., Pomposelli, James J., Conzen, Kendra D., Kriss, Michael S., Burton, James R., Pomfret, Elizabeth A.

“…A gap exists between the demand for pediatric liver transplantation and the supply of appropriate size‐matched donors. We describe our center’s experience with…”
Get full text

Defining Long-term Outcomes With Living Donor Liver Transplantation in North America by Olthoff, Kim M, Smith, Abigail R, Abecassis, Michael, Baker, Talia, Emond, Jean C, Berg, Carl L, Beil, Charlotte A, Burton, James R, Fisher, Robert A, Freise, Chris E, Gillespie, Brenda W, Grant, David R, Humar, Abhinav, Kam, Igal, Merion, Robert M, Pomfret, Elizabeth A, Samstein, Benjamin, Shaked, Abraham

“…OBJECTIVES:To compare long-term survival of living donor liver transplant (LDLT) at experienced transplant centers with outcomes of deceased donor liver…”
Get full text

Highlights From Controversies in Transplantation 2023 Conference by Saben, Jessica L., Kaplan, Bruce, Burton, James R., Cooper, James E., Pomposelli, James J., Schold, Jesse D., Pomfret, Elizabeth A.

Get full text

Liver and Kidney Recipient Selection of Hepatitis C Virus Viremic Donors: Meeting Consensus Report From the 2019 Controversies in Transplantation by Burton, James R., Terrault, Norah A., Goldberg, David S., Bloom, Roy D., Gilroy, Richard, Heimbach, Julie K., Brown, Robert S., Everson, Gregory T., Rubin, Erin, Wiesner, Russ, Pomfret, Elizabeth A.

“…The development of multiple highly effective and safe direct-acting antivirals to treat hepatitis C virus (HCV) has resulted in greater ease and confidence in…”
Get full text

Management of the Transplant Recipient with Chronic Hepatitis C by Burton, James R., MD, Everson, Gregory T., MD

“…More than one-third of listed potential liver recipients in the US are infected with the hepatitis C virus (HCV). Recurrence of infection with HCV after liver…”
Get full text

Pro: Steroids Can Be Withdrawn After Transplant in Recipients With Autoimmune Hepatitis by Kalra, Avash, Burton, James R., Forman, Lisa M.

“…Corticosteroids have been a mainstay of immunosuppression following liver transplantation. However, evolution in the field of transplant immunology has…”
Get full text

Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers by MacBrayne, Christine E, Castillo-Mancilla, Jose, Burton, Jr, James R, MaWhinney, Samantha, Wagner, Charlotte B, Micke, Kestutis, Fey, Jordan, Huntley, Ryan T, Larson, Bayli, Bushman, Lane R, Kiser, Jennifer J

“…Dolutegravir, an HIV integrase strand-transfer inhibitor, and simeprevir, an HCV NS3/4A PI, have the potential to interact as dolutegravir is a P-glycoprotein,…”
Get full text

A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy by Burton, James R, O’Leary, Jacqueline G, Verna, Elizabeth C, Saxena, Varun, Dodge, Jennifer L, Stravitz, Richard T, Levitsky, Joshua, Trotter, James F, Everson, Gregory T, Brown, Robert S, Terrault, Norah A

“…Background & Aims NS3/4A protease inhibitors, boceprevir or telaprevir, combined with peginterferon and ribavirin was the standard treatment for HCV genotype 1…”
Get full text

Choledochoduodenostomy is associated with fewer post‐transplant biliary complications compared to Roux‐en‐Y in primary sclerosing cholangitis patients by Jonica, Emily R., Han, Samuel, Burton, James R., Pomposelli, James J., Shah, Raj J.

“…Background For primary sclerosing cholangitis (PSC) patients undergoing liver transplantation (LT), a consensus regarding biliary reconstruction remains…”
Get full text